Table 3.
Results of the network meta‐analysis: dichotomous variable
| Response rate (≥ 20% reduction in PANSS‐T) | |||
|---|---|---|---|
| LUR40 | 0.918 (0.774, 1.088) | 0.826 (0.716, 0.953) *, a | 0.518, 1.318 |
| 0.963 (0.805, 1.151) | LUR80 | 0.900 (0.763, 1.062) | 0.545, 1.486 |
| 0.826 (0.716, 0.953) | 0.937 (0.789, 1.113) | Placebo | Prediction interval* |
| All‐cause discontinuation | |||
|---|---|---|---|
| LUR40 | 0.905 (0.732, 1.119) | 0.869 (0.713, 1.058) | 0.613, 1.230 |
| 0.927 (0.744, 1.156) | LUR80 | 0.960 (0.765, 1.204) | 0.648, 1.421 |
| 0.892 (0.730, 1.091) | 0.947 (0.739, 1.214) | Placebo | Prediction interval* |
| Discontinuation due to adverse events | |||
|---|---|---|---|
| LUR40 | 0.871 (0.488, 1.556) | 0.879 (0.518, 1.493) | 0.295, 2.623 |
| 0.868 (0.478, 1.577) | LUR80 | 1.010 (0.519, 1.962) | 0.283, 3.605 |
| 0.991 (0.576, 1.706) | 0.748 (0.341, 1.644) | Placebo | Prediction interval* |
| At least one adverse event | |||
|---|---|---|---|
| LUR40 | 0.989 (0.916, 1.067) | 1.031 (0.948, 1.121) | 0.899, 1.182 |
| 0.999 (0.924, 1.079) | LUR80 | 1.042 (0.951, 1.143) | 0.898, 1.210 |
| 1.039 (0.953, 1.133) | 1.049 (0.949, 1.160) | Placebo | Prediction interval* |
| Akathisia | |||
|---|---|---|---|
| LUR40 | 0.684 (0.441, 1.062) | 2.052 (1.139, 3.699) b | 0.788, 5.342 |
| 0.676 (0.431, 1.058) | LUR80 | 2.999 (1.639, 5.488) c | 1.124, 8.000 |
| 2.131 (1.169, 3.884) | 2.791 (1.430, 5.446) | Placebo | Prediction interval* |
| Anxiety | |||
|---|---|---|---|
| LUR40 | 0.899 (0.286, 2.826) | 0.600 (0.241, 1.494) | 0.027, 13.328 |
| 0.883 (0.253, 3.081) | LUR80 | 0.668 (0.225, 1.985) | 0.023, 19.321 |
| 0.631 (0.251, 1.588) | 0.768 (0.244, 2.421) | Placebo | Prediction interval* |
| Constipation | |||
|---|---|---|---|
| LUR40 | 1.292 (0.680, 2.456) | 0.915 (0.531, 1.575) | 0.315, 2.660 |
| 1.259 (0.651, 2.435) | LUR80 | 0.708 (0.373, 1.342) | 0.213, 2.351 |
| 0.946 (0.547, 1.636) | 0.618 (0.319, 1.199) | Placebo | Prediction interval* |
| Diarrhea | |||
|---|---|---|---|
| LUR40 | 1.603 (0.680, 3.782) | 0.757 (0.386, 1.484) | 0.254, 2.259 |
| 1.601 (0.668, 3.837) | LUR80 | 0.472 (0.197, 1.134) | 0.114, 1.958 |
| 0.792 (0.399, 1.570) | 0.428 (0.167, 1.097) | Placebo | Prediction interval* |
| Dizziness | |||
|---|---|---|---|
| LUR40 | 1.045 (0.357, 3.056) | 1.941 (0.737, 5.111) | 0.403, 9.349 |
| 0.997 (0.325, 3.058) | LUR80 | 1.857 (0.548, 6.292) | 0.256, 13.468 |
| 1.962 (0.739, 5.208) | 1.658 (0.399, 6.885) | Placebo | Prediction interval* |
| Dry mouth | |||
|---|---|---|---|
| LUR40 | 0.603 (0.130, 2.805) | 1.451 (0.296, 7.124) | 0.110, 19.215 |
| 0.599 (0.116, 3.085) | LUR80 | 2.407 (0.421, 13.756) | 0.142, 40.809 |
| 1.366 (0.264, 7.056) | 2.063 (0.268, 15.874) | Placebo | Prediction interval* |
| Dystonia | |||
|---|---|---|---|
| LUR40 | 0.499 (0.199, 1.250) | 2.998 (0.724, 12.416) | 0.298, 30.123 |
| 0.499 (0.196, 1.270) | LUR80 | 6.013 (1.508, 23.987) d | 0.636, 56.855 |
| 2.955 (0.702, 12.446) | 5.964 (1.347, 26.406) | Placebo | Prediction interval* |
| Headache | |||
|---|---|---|---|
| LUR40 | 1.364 (0.775, 2.402) | 1.141 (0.727, 1.792) | 0.549, 2.373 |
| 1.342 (0.740, 2.434) | LUR80 | 0.837 (0.470, 1.491) | 0.327, 2.138 |
| 1.114 (0.707, 1.756) | 0.783 (0.420, 1.459) | Placebo | Prediction interval* |
| Insomnia | |||
|---|---|---|---|
| LUR40 | 0.791 (0.498, 1.255) | 0.891 (0.561, 1.416) | 0.314, 2.526 |
| 0.887 (0.548, 1.434) | LUR80 | 1.127 (0.669, 1.898) | 0.371, 3.426 |
| 0.851 (0.529, 1.368) | 1.454 (0.808, 2.615) | Placebo | Prediction interval* |
| Muscle rigidity | |||
|---|---|---|---|
| LUR40 | 1.061 (0.434, 2.593) | 1.444 (0.475, 4.392) | 0.237, 8.789 |
| 1.075 (0.436, 2.646) | LUR80 | 1.361 (0.419, 4.419) | 0.201, 9.212 |
| 1.589 (0.501, 5.042) | 1.312 (0.352, 4.888) | Placebo | Prediction interval* |
| Nausea | |||
|---|---|---|---|
| LUR40 | 1.130 (0.664, 1.925) | 1.227 (0.644, 2.337) | 0.367, 4.105 |
| 1.217 (0.710, 2.084) | LUR80 | 1.085 (0.543, 2.168) | 0.303, 3.885 |
| 1.205 (0.620, 2.343) | 1.281 (0.597, 2.748) | Placebo | Prediction interval* |
| Rash | |||
|---|---|---|---|
| LUR40 | 0.864 (0.249, 2.993) | 0.808 (0.257, 2.543) | 0.126, 5.199 |
| 0.807 (0.217, 2.995) | LUR80 | 0.936 (0.271, 3.237) | 0.125, 7.018 |
| 0.826 (0.253, 2.696) | 0.960 (0.251, 3.670) | Placebo | Prediction interval* |
| Schizophrenia | |||
|---|---|---|---|
| LUR40 | 0.755 (0.495, 1.150) | 0.633 (0.442, 0.907) e | 0.353, 1.135 |
| 0.751 (0.479, 1.177) | LUR80 | 0.839 (0.572, 1.231) | 0.450, 1.564 |
| 0.636 (0.442, 0.914) | 0.826 (0.555, 1.230) | Placebo | Prediction interval* |
| Serious adverse event | |||
|---|---|---|---|
| LUR40 | 1.137 (0.526, 2.458) | 0.831 (0.416, 1.660) | 0.270, 2.556 |
| 1.197 (0.546, 2.626) | LUR80 | 0.731 (0.336, 1.591) | 0.207, 2.585 |
| 0.841 (0.418, 1.690) | 0.768 (0.343, 1.718) | Placebo | Prediction interval* |
| Somnolence | |||
|---|---|---|---|
| LUR40 | 1.135 (0.640, 2.010) | 4.799 (1.539, 14.969) f | 0.757, 30.435 |
| 1.093 (0.615, 1.944) | LUR80 | 4.230 (1.326, 13.496) g | 0.643, 27.827 |
| 4.717 (1.444, 15.404) | 3.307 (0.919, 11.898) | Placebo | Prediction interval* |
| Tremor | |||
|---|---|---|---|
| LUR40 | 0.559 (0.289, 1.080) | 0.882 (0.418, 1.865) | 0.262,2.974 |
| 0.498 (0.251, 0.988) | LUR80 | 1.579 (0.804, 3.101) | 0.528,4.724 |
| 0.883 (0.394, 1.979) | 1.482 (0.725, 3.027) | Placebo | Prediction interval* |
| Use of sleeping pills | |||
|---|---|---|---|
| LUR40 | 1.007 (0.896, 1.131) | 1.017 (0.908, 1.139) | 0.793, 1.304 |
| 1.014 (0.901, 1.140) | LUR80 | 1.010 (0.897, 1.137) | 0.779, 1.310 |
| 1.017 (0.908, 1.139) | 1.019 (0.903, 1.149) | Placebo | Prediction interval* |
| Use of anxiolytic | |||
|---|---|---|---|
| LUR40 | 0.949 (0.837, 1.075) | 1.030 (0.909, 1.167) | 0.783, 1.354 |
| 0.969 (0.853, 1.102) | LUR80 | 1.086 (0.952, 1.238) | 0.813, 1.449 |
| 1.031 (0.910, 1.168) | 1.116 (0.974, 1.279) | Placebo | Prediction interval* |
| Use of Anticholinergic drugs | |||
|---|---|---|---|
| LUR40 | 0.989 (0.672, 1.456) | 1.475 (0.938, 2.318) | 0.449, 4.840 |
| 0.950 (0.643, 1.404) | LUR80 | 1.491 (0.932, 2.386) | 0.446, 4.982 |
| 1.593 (0.997, 2.547) | 1.289 (0.780, 2.130) | Placebo | Prediction interval* |
| Vomiting | |||
|---|---|---|---|
| LUR40 | 0.869 (0.508, 1.487) | 1.241 (0.657, 2.346) | 0.442, 3.489 |
| 0.886 (0.516, 1.522) | LUR80 | 1.428 (0.757, 2.694) | 0.509, 4.004 |
| 1.291 (0.672, 2.481) | 1.508 (0.781, 2.913) | Placebo | Prediction interval* |
| Weight gain (≥ 7%) | |||
|---|---|---|---|
| LUR40 | 3.057 (0.985, 9.482) | 2.589 (1.065, 6.293) h | 0.368, 18.198 |
| 2.684 (0.842, 8.558) | LUR80 | 0.847 (0.245, 2.926) | 0.056, 12.874 |
| 2.532 (1.034, 6.200) | 0.792 (0.214, 2.939) | Placebo | Prediction interval* |
| Weight loss (≥ 7%) | |||
|---|---|---|---|
| LUR40 | 1.760 (0.892, 3.474) | 0.835 (0.501, 1.391) | 0.272, 2.559 |
| 1.787 (0.895, 3.567) | LUR80 | 0.474 (0.245, 0.920) i | 0.111, 2.031 |
| 0.836 (0.502, 1.393) | 0.477 (0.244, 0.933) | Placebo | Prediction interval* |
| QTcF interval 450msec | |||
|---|---|---|---|
| LUR40 | 1.145 (0.418, 3.135) | 0.990 (0.411, 2.385) | 0.136, 7.182 |
| 1.018 (0.359, 2.890) | LUR80 | 0.864 (0.319, 2.338) | 0.093, 8.035 |
| 1.047 (0.431, 2.542) | 0.833 (0.294, 2.356) | Placebo | Prediction interval* |
Risk ratio (95%CrI).
Results from pair‐wise meta‐analysis are presented in the left lower half and results from network meta‐analysis in the upper right half.
The bold‐face value indicated the statistically significant.
95%CrI: 95% credible interval, LUR: lurasidone, NNTB (NNTH): number needed to treat to benefit (harm), PANSS‐T: Positive and Negative Syndrome Scale total score.
a
NNTB (95%CrI): 8.9 (5.6, 21.7).
b
NNTH (95%CrI): 34.5 (19.2, 200.0).
c
NNTH (95%CrI): 14.1 (9.1, 31.2).
d
NNTH (95%CrI): 32.3 (19.2, 111.1).
e
NNTH (95%CrI): 25.6 (13.7, 200.0).
f
NNTH (95%CrI): 33.3 (21.7, 76.9).
g
NNTH (95%CrI): 43.5 (21.7, 1000.0).
h
NNTH (95%CrI): 47.6 (25.6, 333.3).
i
NNTH (95%CrI): 24.4 (13.3, 142.9).
*
Prediction interval when comparing active drug with placebo.